Chinese Journal of New Drugs 2010 Issue 18 Trends in the development of new combination antihypertensive drugs in China

Trends in the development of new combination antihypertensive drugs in China
HUA Cong-xiao;KANG Cai-lian

..............page:1652-1656

..............page:1631-1632

Pharmacokinetics of a new derivative of ginkgolide B and its absolute bioavailability in Beagle dogs
WANG Dian-lei1;2;3;CHEN Wei-dong3;ZHANG Rui3;LIANG Yan2;WANG Xin-ting2;XIE Tong2;XIE Lin2;LIU Xiao-dong2

..............page:1710-1713,1718

Pharmacokinetics of a new derivative of ginkgolide B and its absolute bioavailability in Beagle dogs
WANG Dian-lei1;2;3;CHEN Wei-dong3;ZHANG Rui3;LIANG Yan2;WANG Xin-ting2;XIE Tong2;XIE Lin2;LIU Xiao-dong2

..............page:1710-1713,1718

WINDOW OF NEW DRUGS

..............page:1631-1632

Preparation and optimization of sustained-release tablets of propafenone hydrochloride β-CD inclusion complex
YIN Li-fang1;GENG Wen-jun1;ZHOU Jian-ping1;ZHU Chun-li1;ZHANG Lu-yong2

..............page:1657-1660,1668

Process analysis and comparison of dissolution of ambroxol hydrochloride tablets from different manufactories
YANG Shu-mei1;KONG Bin2;LI Xin-xia3;CHEN Jian3

..............page:1722-1725

Pharmacology and clinical evaluation of enalapril maleate and folic acid tablet
HUO Yong1;CHEN Guang-liang2;XU Xi-ping2;3

..............page:1633-1636

A fixed-dose combination of amlodipine/atorvastatin: Caduet
WU Ping-sheng;TAO Yu

..............page:1637-1641,1647

Progress in research of platelet integrin receptors and related drugs
XIONG Jing;FU Jian-yang;LI Yun-man

..............page:1688-1693

Principles and future changes in antihypertensive
WANG Ji-guang

..............page:1669-1670,1693

Relationship between metoprolol-induced dyslipidemia and β_2-adrenergic receptor polymorphisms
LIU Li-wei;CHEN Guo-liang;LIU Hong;LI Na;LIU Yu-qing;LI Yi-shi

..............page:1661-1665

Technical requirements from ICH for preclinical cardiac safety evaluation of pharmaceuticals
CHEN Long1;YANG Lin2;Lu Qiang3;ZHANG Zhi-hao4;ZHAI Jin5;ZHANG Jun-ze6

..............page:1642-1647

Trends in the development of new combination antihypertensive drugs in China
HUA Cong-xiao;KANG Cai-lian

..............page:1652-1656

Preparation and optimization of sustained-release tablets of propafenone hydrochloride β-CD inclusion complex
YIN Li-fang1;GENG Wen-jun1;ZHOU Jian-ping1;ZHU Chun-li1;ZHANG Lu-yong2

..............page:1657-1660,1668

Efficacy of compound Danshen drop pill in 42 patients with early acute myocardial infarction
LI Xu-feng;LIU Fu;JIANG Ting-li;WANG Zi-jian;HAN Yu-hai;WU Zhi-hong

..............page:1699-1702

Process analysis and comparison of dissolution of ambroxol hydrochloride tablets from different manufactories
YANG Shu-mei1;KONG Bin2;LI Xin-xia3;CHEN Jian3

..............page:1722-1725

zhong guo xin yao za zhi tou gao xu zhi

..............page:1731-1732

Determination of quercetin in Baweichenxiang capsule by HPLC
WANG Wei1;HAN Jiang-wei2;SUN Li-jun2;WANG Yu-hua2

..............page:1719-1721

Technical requirements from ICH for preclinical cardiac safety evaluation of pharmaceuticals
CHEN Long1;YANG Lin2;Lu Qiang3;ZHANG Zhi-hao4;ZHAI Jin5;ZHANG Jun-ze6

..............page:1642-1647

2010 zhong guo sheng wu yao wu chuang xin yan jiu lun tan 2010 ban zhong guo yao dian shi yong jie du yan tao

..............page:1721

Preparation of self-microemulsifying semi-solid matrix hard capsules of daidzein and its pharmacokinetics in rats
CUI Wen-qi;WANG Dong-kai;HAN Xiao;ZHANG Chun-ye;LI Xiang;ZHANG Xiao-jun

..............page:1714-1718

Relationship between metoprolol-induced dyslipidemia and β_2-adrenergic receptor polymorphisms
LIU Li-wei;CHEN Guo-liang;LIU Hong;LI Na;LIU Yu-qing;LI Yi-shi

..............page:1661-1665

Principles and future changes in antihypertensive
WANG Ji-guang

..............page:1669-1670,1693

2010 zhong guo sheng wu yao wu chuang xin yan jiu lun tan 2010 ban zhong guo yao dian shi yong jie du yan tao

..............page:1721

Determination of quercetin in Baweichenxiang capsule by HPLC
WANG Wei1;HAN Jiang-wei2;SUN Li-jun2;WANG Yu-hua2

..............page:1719-1721

zhong guo xin yao za zhi tou gao xu zhi

..............page:1731-1732

Pharmacology and clinical evaluation of enalapril maleate and folic acid tablet
HUO Yong1;CHEN Guang-liang2;XU Xi-ping2;3

..............page:1633-1636

tian shi li fu fang dan can di wan shun li tong guo mei guo fda qi lin chuang shi yan
dan yang ;';'';'au';'cjfq');

..............page:1626

Progress in research of platelet integrin receptors and related drugs
XIONG Jing;FU Jian-yang;LI Yun-man

..............page:1688-1693

A fixed-dose combination of amlodipine/atorvastatin: Caduet
WU Ping-sheng;TAO Yu

..............page:1637-1641,1647

Therapeutic efficacy of simvastatin in patients with low ankle brachial index
WANG Kun1;HU Da-yi2

..............page:1703-1705

Efficacy of compound Danshen drop pill in 42 patients with early acute myocardial infarction
LI Xu-feng;LIU Fu;JIANG Ting-li;WANG Zi-jian;HAN Yu-hai;WU Zhi-hong

..............page:1699-1702

Preparation of self-microemulsifying semi-solid matrix hard capsules of daidzein and its pharmacokinetics in rats
CUI Wen-qi;WANG Dong-kai;HAN Xiao;ZHANG Chun-ye;LI Xiang;ZHANG Xiao-jun

..............page:1714-1718

Progress in the international development of combination medicines for hypertension
DU Hai-zhou;LIU Na;LIU Gui-ling;WANG Tian-jin;L Ting

..............page:1676-1679

zhong guo xin xue guan bing kong zhi de gen ben chu lu zai yu fang
hu da yi ;';'';'au';'cjfq');

..............page:1627

ben qi dao du

..............page:1623

Clinical study on Shenmaikang capsule in treating stable angina pectoris (Qi deficiency and Blood stasis type)
WANG Guang-yan1;GU Ning2

..............page:1694-1698

Clinical pharmacokinetics of fluvastatin extended release formulation
LUO Xiao;SHI Li-min;WANG Ru-long

..............page:1680-1683

Advances in pharmacological effects and clinical application of atorvastatin
WANG Zhen-yu1;YU Tong-sheng1;WANG Jian1;ZHANG Xin2

..............page:1684-1687,1698

di san jie quan guo yao wu xing sun hai yu an quan yong yao xue shu hui yi nei fen mi dai xie ji bing yong yao an quan yu yao yuan xing nei fen mi dai xie ji bing fang zhi zhuan ti yan tao hui zheng wen tong zhi

..............page:1651

tian shi li fu fang dan can di wan shun li tong guo mei guo fda qi lin chuang shi yan
dan yang ;';'';'au';'cjfq');

..............page:1626

Advances in pharmacological effects and clinical application of atorvastatin
WANG Zhen-yu1;YU Tong-sheng1;WANG Jian1;ZHANG Xin2

..............page:1684-1687,1698

Clinical pharmacokinetics of fluvastatin extended release formulation
LUO Xiao;SHI Li-min;WANG Ru-long

..............page:1680-1683

Optimized choice of antihypertensive drugs for the components of fixed dose combination formula: clinical significance of ARB+CCB
LI Yong

..............page:1671-1675

Clinical study on Shenmaikang capsule in treating stable angina pectoris (Qi deficiency and Blood stasis type)
WANG Guang-yan1;GU Ning2

..............page:1694-1698

ben qi dao du

..............page:1623

di san jie quan guo yao wu xing sun hai yu an quan yong yao xue shu hui yi nei fen mi dai xie ji bing yong yao an quan yu yao yuan xing nei fen mi dai xie ji bing fang zhi zhuan ti yan tao hui zheng wen tong zhi

..............page:1651

Ginaton injection-induced hypotension in an old patient
LI Zheng

..............page:1729-1730

zhong guo xin xue guan bing kong zhi de gen ben chu lu zai yu fang
hu da yi ;';'';'au';'cjfq');

..............page:1627

Therapeutic efficacy of simvastatin in patients with low ankle brachial index
WANG Kun1;HU Da-yi2

..............page:1703-1705

Synthesis of the antihypertensive drug telmisartan
XIAO Shi-jun1;YANG Xue-yan1;WU Fan-hong2;WANG Fei1

..............page:1726-1728

Progress in the international development of combination medicines for hypertension
DU Hai-zhou;LIU Na;LIU Gui-ling;WANG Tian-jin;L Ting

..............page:1676-1679

Ginaton injection-induced hypotension in an old patient
LI Zheng

..............page:1729-1730

Optimized choice of antihypertensive drugs for the components of fixed dose combination formula: clinical significance of ARB+CCB
LI Yong

..............page:1671-1675

Synthesis of the antihypertensive drug telmisartan
XIAO Shi-jun1;YANG Xue-yan1;WU Fan-hong2;WANG Fei1

..............page:1726-1728

Reappraisal of anti-hypertensive drugs in the 2009 edition of European guidelines on hypertension management
GUO Yi-fang

..............page:1666-1668

Reappraisal of anti-hypertensive drugs in the 2009 edition of European guidelines on hypertension management
GUO Yi-fang

..............page:1666-1668

xin xue guan ling yu san shi nian yan jiu hui gu
hu da yi ;';'05964076;';'au';'cjfq');

..............page:1628-1630

xin xue guan ling yu san shi nian yan jiu hui gu
hu da yi ;';'05964076;';'au';'cjfq');

..............page:1628-1630

"FDA's strategic plan for risk communication" and its implication in China
NING Yan-yang;YANG Yue

..............page:1648-1651

Evaluation of hemostatic effects of Haemocoagulase Agkistrodon and the mechanisms
SHI Guang;PANG Jian-xin;KONG Huan-yu;LUO Chao;LIU Ai-ming;JIN Hong;CAO Ying

..............page:1706-1709

Evaluation of hemostatic effects of Haemocoagulase Agkistrodon and the mechanisms
SHI Guang;PANG Jian-xin;KONG Huan-yu;LUO Chao;LIU Ai-ming;JIN Hong;CAO Ying

..............page:1706-1709

"FDA's strategic plan for risk communication" and its implication in China
NING Yan-yang;YANG Yue

..............page:1648-1651